Survival of patients with mucosal melanoma in Cali, Colombia: a retrospective cohort study
By: García, Ana M., Parra-Lara, Luis G., Mendoza-Urbano, Diana M., Bravo, Juan C., Zambrano Harvey, Ángela

BioMed Central
2024-07-23; doi: 10.1186/s12885-024-12371-x

Abstract

Background

Mucosa melanoma is a rare condition with aggressive behavior and a less favorable prognosis compared to cutaneous melanoma. The objective of this study was to estimate the overall survival and clinical outcomes of patients diagnosed with mucosal melanoma in a Colombian hospital.

Methods

A retrospective cohort study was conducted at Fundación Valle del Lili, a single center located in Cali, Colombia. Patients aged ≥ 18 years, both sexes, diagnosed with mucosal melanoma by histopathology study were included between 2010–2019. Patients who received extra-institutional treatment or whose vital status was unknown during follow-up were excluded. Demographic, clinical and laboratory data were obtained from medical records and laboratory and pathology databases. A descriptive analysis was performed. Survival analysis was conducted using the Kaplan–Meier method.

Results

A total of 23 patients were included. Median age was 63 years old (IQR: 57–68) and 52.2% were woman. Clinical stage was 34.8% early, 26.1% locally advanced and 39.1% metastatic. The main primary locations were nasopharynx (30.4%), genitals (26.1%), rectum (21.7%), oral cavity (13%) and paranasal sinuses (8.7%). The majority received surgery (30.4%) and immunotherapy (26.1%) as first line treatment.

Overall survival at one year was 80.8%, at three years 44.3%, and at five years 36.9%.

Conclusion

Mucosal melanoma is a rare, aggressive disease with adverse oncological outcomes due to late diagnosis and limited treatment options. This study provides real-world data in a single-center of Colombia.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements